Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study

MLA

Giovanna Borriello, et al. “Cladribine Effects on Patient-Reported Outcomes and Their Clinical and Biometric Correlates in Highly Active Relapsing Multiple Sclerosis at First Switch: The Observational, Multicenter, Prospective, Phase IV CLADFIT-MS Study.” Frontiers in Neurology, vol. 15, July 2024. EBSCOhost, https://doi.org/10.3389/fneur.2024.1422078.

APA

Giovanna Borriello, Clara Grazia Chisari, Davide Maimone, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, & Francesco Patti. (2024). Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1422078

Chicago

Giovanna Borriello, Clara Grazia Chisari, Davide Maimone, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, and Francesco Patti. 2024. “Cladribine Effects on Patient-Reported Outcomes and Their Clinical and Biometric Correlates in Highly Active Relapsing Multiple Sclerosis at First Switch: The Observational, Multicenter, Prospective, Phase IV CLADFIT-MS Study.” Frontiers in Neurology 15 (July). doi:10.3389/fneur.2024.1422078.